PMC2728198_01
Pre- and post-treatment MRI (sagittal) illustrating the reduction in tumor size
cln64_8p819f1.jpg
PMC2728198_01_cln64_8p819f1.jpg
f1-cln64_8p819
An MRI of the abdomen and pelvis demonstrated a well-demarcated solid pelvic mass (9.3 cm x 8.3 cm x 6.5 cm; 257 cc) (Figures 1 and 2) compressing the bladder, prostate and rectum. An MRI after 6 weeks of imatinib mesylate treatment demonstrated a marked reduction in tumor size (6.3 cm x 5.6 cm x 4.7 cm; 86 cc) (Figure 1 and 2).
Pre- and post-treatment MRI illustrating the reduction in tumor size
cln64_8p819f2.jpg
PMC2728198_01_cln64_8p819f2.jpg
f2-cln64_8p819
An MRI of the abdomen and pelvis demonstrated a well-demarcated solid pelvic mass (9.3 cm x 8.3 cm x 6.5 cm; 257 cc) (Figures 1 and 2) compressing the bladder, prostate and rectum. An MRI after 6 weeks of imatinib mesylate treatment demonstrated a marked reduction in tumor size (6.3 cm x 5.6 cm x 4.7 cm; 86 cc) (Figure 1 and 2).